Human Papillomavirus Type 16 and 18 E6 and E7 Oncoproteins (HPV16/18 E6/E7)

Human Papillomavirus (HPV) Type 16 and 18 E6 and E7 oncoproteins are the primary drivers of malignancy in high-risk HPV infections, which are responsible for the vast majority of cervical cancers as well as significant proportions of oropharyngeal, anal, and vulvar cancers [1, 4]. The E6 protein facilitates the ubiquitin-mediated degradation of the tumor suppressor p53, while the E7 protein binds and inactivates the retinoblastoma protein (pRb), collectively leading to the evasion of apoptosis, uncontrolled cell cycle progression, and genomic instability [5, 13]. Because these viral proteins are constitutively expressed in HPV-transformed cells and are absent in healthy human tissues, they represent ideal tumor-specific antigens for therapeutic intervention [6, 11]. Current therapeutic strategies focus on vaccines (DNA, peptide, and viral vector-based) and adoptive T-cell therapies designed to elicit a robust cytotoxic T-lymphocyte response against E6/E7-expressing cells [1, 15]. Additionally, experimental approaches such as CRISPR/Cas9 gene editing and small-molecule inhibitors are being explored to directly disrupt the function of these oncoproteins and restore host tumor suppressor activity [7, 10, 12].

Other names

HPV16 E6HPV16 E7HPV18 E6HPV18 E7High-risk HPV oncoproteinsHPV16/18 E6/E7HPV oncoprotein-expressing cells

Induction of antigen-specific T-cell mediated cytotoxicity against cells expressing viral oncoproteins; restoration of p53 and pRb tumor suppressor pathways through inhibition or degradation of E6 and E7 [1, 6, 7].